Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYFQJL)

• Drug Name: BNV-222 Drug Info
• Synonyms: Diepalrestat choline; UNII-16AHE7410O; 16AHE7410O; CHEMBL4297277; Q27251797; 1665300-21-9; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, (5Z)-5-((2E)-2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-3-thiazolidineacetate, (5Z)-5-((2E)-2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-3-thiazolidineacetate (1:1:1)

Indication

Disease Entry	ICD 11	Status	REF
Diabetic neuropathy	8C0Z	Phase 2/3	[1]

• Cross-matching ID:
  PubChem CID: 117587644
  CAS Number: CAS 1665300-21-9
  TTD Drug ID: DMYFQJL

Molecule-Related Drug Atlas

Drug(s) Targeting Aldose reductase (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[3]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[4]
Fidarestat	DMZL1I8	Diabetic complication	5A2Y	Phase 3	[5]
Ranirestat	DMD5QRS	Diabetic neuropathy	8C0Z	Phase 3	[2]
CONTIGOSIDE B	DMX9V8K	Thrombosis	DB61-GB90	Phase 2/3	[6]
LIDORESTAT	DMA0RI9	Diabetic complication	5A2Y	Phase 2	[7]
QR-333	DMKVIWM	Diabetic neuropathy	8C0Z	Phase 2	[8]
ADMVA	DM819CO	Diabetic complication	5A2Y	Phase 2	[2]
M-16209	DMZ7YX3	Diabetic complication	5A2Y	Phase 2	[9]
T2c-003	DMWIH59	Diabetic neuropathy	8C0Z	Phase 1/2	[2]
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[3]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[4]
Fidarestat	DMZL1I8	Diabetic complication	5A2Y	Phase 3	[5]
Ranirestat	DMD5QRS	Diabetic neuropathy	8C0Z	Phase 3	[2]
CONTIGOSIDE B	DMX9V8K	Thrombosis	DB61-GB90	Phase 2/3	[6]
LIDORESTAT	DMA0RI9	Diabetic complication	5A2Y	Phase 2	[7]
QR-333	DMKVIWM	Diabetic neuropathy	8C0Z	Phase 2	[8]
ADMVA	DM819CO	Diabetic complication	5A2Y	Phase 2	[2]
M-16209	DMZ7YX3	Diabetic complication	5A2Y	Phase 2	[9]
T2c-003	DMWIH59	Diabetic neuropathy	8C0Z	Phase 1/2	[2]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aldose reductase (AKR1B1)	TTFBNVI	ALDR_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
• [3] Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
• [4] Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
• [5] Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
• [6] Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
• [7] Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
• [8] A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
• [9] Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91.